
CVAC
Healthcare · Biotechnology · $1.05B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now · +33.8% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 29, 2026 | Time not confirmed | -0.07 | 0.00 | +100.0% |
| Nov 24, 2025 | Time not confirmed | -0.15 | -0.07 | +53.3% |
| Aug 15, 2025 | Time not confirmed | -0.05 | -0.26 | -466.4% |
| May 21, 2025 | Before the open | -0.19 | -0.16 | +17.7% |
| Nov 12, 2024 | Before the open | 0.61 | 1.50 | +145.9% |
| Aug 15, 2024 | Before the open | -0.26 | -0.35 | -33.9% |
| Apr 25, 2024 | Before the open | -0.18 | -0.39 | -116.7% |
| Mar 12, 2024 | Before the open | -0.20 | -0.42 | -110.0% |
| Nov 14, 2023 | Before the open | -0.23 | -0.22 | +4.3% |
| Aug 17, 2023 | Before the open | -0.24 | -0.30 | -25.0% |
| May 30, 2023 | After the close | -0.34 | -0.27 | +20.6% |
| Nov 16, 2022 | After the close | -0.27 | -0.25 | +7.4% |
| Aug 18, 2022 | Before the open | -0.26 |
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the…
| -0.31 |
| -19.2% |
| May 25, 2022 | After the close | -0.50 | -0.08 | +84.0% |
| Nov 18, 2021 | After the close | -0.85 | -0.77 | +9.4% |
| Aug 16, 2021 | Time not confirmed | -0.85 | -0.82 | +2.9% |
| Apr 15, 2021 | Before the open | -0.51 | -0.33 | +35.3% |
| Nov 30, 2020 | After the close | -0.35 | -0.24 | +31.4% |
| Aug 14, 2020 | After the close | -54.37 | -0.29 | +99.5% |